Shockwave Medical, Inc. SWAV recently announced the full U.S. commercial availability of the Shockwave L6 Peripheral Intravascular Lithotripsy (IVL) Catheter. This follows the receipt of the FDA’s ...

Shockwave C2+ Catheter Expands Utility of IVL in Calcified Coronary Arteries Shockwave C2+ is commercially available for the treatment of de novo coronary artery disease in Europe and select other ...

2015 Fierce 15 company Shockwave Medical is going public, filing for a $75 million IPO on the Nasdaq with the ticker symbol SWAV. The Santa Clara, California-based company manufactures an ...

A detailed agenda for all Shockwave Medical symposia and featured presentations can be found here. While under clinical investigation in the COSIRA-II trial (U.S. and Canada), the Reducer is CE-marked ...

Johnson & Johnson has announced the European launch of its Shockwave Javelin Peripheral IVL Catheter, an intravascular lithotripsy (IVL) platform aimed at addressing calcium buildup in severely ...

“The Shockwave L 6 catheter pushes the boundaries of what IVL can help physicians achieve for patients with severe peripheral arterial disease,” said Frank Arko, M.D., Chief of Vascular and ...

Johnson & Johnson MedTech’s Shockwave Medical has launched its Javelin Peripheral IVL Catheter in the US for peripheral artery disease (PAD). This new intravascular lithotripsy (IVL) platform is ...

Analyst William Plovanic of Canaccord Genuity maintained a Buy rating on Shockwave Medical (SWAV – Research Report), with a price target of $294.00. William Plovanic’s Buy rating for Shockwave Medical ...

SANTA CLARA, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified ...

A rendering of the Lithoplasty balloon catheter, screenshot--Courtesy of Shockwave Medical Medical device makers are scrambling to develop and sell advanced angioplasty balloons to treat peripheral ...